Cargando…

Low dose anti-thymocyte globulin with low dose posttransplant cyclophosphamide (low dose ATG/PTCy) can reduce the risk of graft-versus-host disease as compared with standard-dose anti-thymocyte globulin in haploidentical peripheral hematopoietic stem cell transplantation combined with unrelated cord blood

Detalles Bibliográficos
Autores principales:	Xu, Xiaoqian, Yang, Jun, Cai, Yu, Li, Su, Niu, Jiahua, Zhou, Kun, Jiang, Ying, Xu, Xiaowei, Shen, Chang, Huang, Chongmei, Qiu, Huiying, Wei, Daolin, Kang, Mei, Tong, Yin, Wei, Zheng, Liu, Peng, Wan, Liping, Song, Xianmin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7943423/ https://www.ncbi.nlm.nih.gov/pubmed/32873913 http://dx.doi.org/10.1038/s41409-020-01047-2

Ejemplares similares

Low-Dose Anti-Thymocyte Globulin Plus Low-Dose Posttransplant Cyclophosphamide as an Effective Regimen for Prophylaxis of Graft Versus Host Disease After Haploidentical Peripheral Blood Stem Cell Transplantation With Maternal/Collateral Related Donors
por: Li, Ting, et al.
Publicado: (2022)

Low-dose post-transplant cyclophosphamide and anti-thymocyte globulin as an effective strategy for GVHD prevention in haploidentical patients
por: Wang, Yu, et al.
Publicado: (2019)

Low-dose anti-thymocyte globulin plus low-dose posttransplant cyclophosphamide as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation combined with unrelated cord blood for patients with hematologic malignancies: a prospective, phase II study
por: Yang, Jun, et al.
Publicado: (2018)

Modified combination of anti-thymocyte globulin (ATG) and post-transplant cyclophosphamide (PTCy) as compared with standard ATG protocol in haploidentical peripheral blood stem cell transplantation for acute leukemia
por: Barkhordar, Maryam, et al.
Publicado: (2022)

Haploidentical hematopoietic stem cell transplantation with one-day posttransplant cyclophosphamide and anti-thymocyte globulin for graft failure
por: Imanaga, Hiroshi, et al.
Publicado: (2020)

T‐cell replete haploidentical stem cell transplantation with low dose anti‐thymocyte globulin for relapsed/refractory Ewing sarcoma family tumors
por: Sano, Hideki, et al.
Publicado: (2021)

Low-dose anti-thymocyte globulin plus low-dose post-transplant cyclophosphamide-based regimen for prevention of graft-versus-host disease after haploidentical peripheral blood stem cell transplants: a large sample, long-term follow-up retrospective study
por: Li, Xingying, et al.
Publicado: (2023)

Very Low Dose Anti-Thymocyte Globulins Versus Basiliximab in Non-Immunized Kidney Transplant Recipients
por: Masset, Christophe, et al.
Publicado: (2023)

Study protocol: Minimum effective low dose: anti-human thymocyte globulin (MELD-ATG): phase II, dose ranging, efficacy study of antithymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes
por: Wilhelm-Benartzi, Charlotte S, et al.
Publicado: (2021)

Lower Absolute Lymphocyte Count Before Conditioning Predicts High Relapse Risk in Patients After Haploidentical Peripheral Blood Stem Cell Transplantation With Low Dose Anti-Thymocyte Globulin/Post-Transplant Cyclophosphamide for GvHD Prophylaxis
por: Zhou, Xiao, et al.
Publicado: (2022)

Outcome Comparison between Low-Dose Rabbit Anti-Thymocyte Globulin and Basiliximab in Low-Risk Living Donor Kidney Transplantation
por: Kim, Sang Jin, et al.
Publicado: (2020)

Low-dose antithymocyte globulin plus low-dose posttransplant cyclophosphamide combined with cyclosporine and mycophenolate mofetil for prevention of graft-versus-host disease after HLA-matched unrelated donor peripheral blood stem cell transplantation
por: Sun, Xi, et al.
Publicado: (2021)

Prolonged, Low-Dose Anti-Thymocyte Globulin, Combined with CTLA4-Ig, Promotes Engraftment in a Stringent Transplant Model
por: D’Addio, Francesca, et al.
Publicado: (2013)

Anti-thymocyte globulin in haematology: Recent developments
por: Siddiqui, Salahuddin, et al.
Publicado: (2019)

Aplastic Anemia Preconditioned with Fludarabine, Cyclophosphamide, and Anti-Thymocyte Globulin
por: Yang, Dan, et al.
Publicado: (2019)

Modest dose anti-thymocyte globulin administered intraoperatively is safe and effective in kidney transplantations: a retrospective study
por: Liu, Hui-Ying, et al.
Publicado: (2019)

Evaluating anti-thymocyte globulin induction doses for better allograft and patient survival in Asian kidney transplant recipients
por: Shim, Ye Eun, et al.
Publicado: (2023)

Allogeneic peripheral blood stem cell transplantation with anti-thymocyte globulin versus allogeneic bone marrow transplantation without anti-thymocyte globulin
por: Baron, Frédéric, et al.
Publicado: (2020)

Does rabbit anti-thymocyte globulin dose and antiviral prophylaxis alter the risk of the development of PTLD in renal transplant population?
por: Mohamed, Mahmoud, et al.
Publicado: (2020)

Impact of anti-thymocyte globulin dose for graft-versus-host disease prophylaxis in allogeneic hematopoietic cell transplantation from matched unrelated donors: a multicenter experience
por: Butera, Sara, et al.
Publicado: (2021)

Anti-Thymocyte Globulin (ATG)-Free Nonmyeloablative Haploidentical PBSCT Plus Post-Transplantation Cyclophosphamide Is a Safe and Efficient Treatment Approach for Pediatric Acquired Aplastic Anemia
por: Chen, Rong-Long, et al.
Publicado: (2022)

Therapy of severe aplastic anemia with anti-human thymocyte globulin (ATGAM) with and without HLA-haploidentical bone-marrow infusion.
por: Kim, K. Y.
Publicado: (1986)

Induction of procalcitonin in liver transplant patients treated with anti-thymocyte globulin
por: Zazula, Roman, et al.
Publicado: (2007)

Rabbit anti‐thymocyte globulin for the prevention of acute rejection in kidney transplantation
por: Alloway, Rita R., et al.
Publicado: (2019)

Myeloid-derived suppressor cells are bound and inhibited by anti-thymocyte globulin
por: Suk Lee, Young, et al.
Publicado: (2019)

Similar transplant outcomes between haploidentical and unrelated donors after reduced-intensity conditioning with busulfan, fludarabine, and anti-thymocyte globulin in patients with acute leukemia or myelodysplastic syndrome
por: Choi, Mihong, et al.
Publicado: (2020)

Post-transplant cyclophosphamide versus anti-thymocyte globulin for graft-versus-host disease prevention in haploidentical transplantation for adult acute lymphoblastic leukemia
por: Nagler, Arnon, et al.
Publicado: (2020)

A prospective, randomized, non-blinded, non-inferiority pilot study to assess the effect of low-dose anti-thymocyte globulin with low-dose tacrolimus and early steroid withdrawal on clinical outcomes in non-sensitized living-donor kidney recipients
por: Ko, Youngmin, et al.
Publicado: (2023)

What is the minimum adequate busulfan dose for patients with sickle cell disease undergoing reduced intensity conditioning with fludarabine, busulfan, and anti‐thymocyte globulin?
por: AlJohani, Naif I., et al.
Publicado: (2021)

Comparison of Alemtuzumab and Anti-thymocyte Globulin Treatment for Acute Kidney Allograft Rejection
por: van der Zwan, Marieke, et al.
Publicado: (2020)

Anti Thymocyte Globulin-Based Treatment for Acquired Bone Marrow Failure in Adults
por: Tjon, Jennifer M.-L., et al.
Publicado: (2021)

Anti‐thymocyte globulin‐mediated immunosenescent alterations of T cells in kidney transplant patients
por: Lee, Ga Hye, et al.
Publicado: (2022)

Low-dose PTCy plus low-dose ATG as GVHD prophylaxis after UD-PBSCT for hematologic malignancies: a prospective, multicenter, randomized controlled trial
por: Zu, Yingling, et al.
Publicado: (2023)

Hematopoietic Stem Cell Transplantation From a Related Donor with Human Leukocyte Antigen 1-Antigen Mismatch in the Graft-Versus-Host Direction Using Low-dose Anti-thymocyte Globulin
por: Kanda, Junya, et al.
Publicado: (2020)

Anti-thymocyte globulin induced non-cardiogenic pulmonary edema during renal transplantation
por: Parikh, Beena K., et al.
Publicado: (2011)

Induction by anti-thymocyte globulins in kidney transplantation: a review of the literature and current usage
por: Malvezzi, Paolo, et al.
Publicado: (2015)

Usefulness of valacyclovir prophylaxis for cytomegalovirus infection after anti-thymocyte globulin as rejection therapy
por: Ko, Eun Jeong, et al.
Publicado: (2019)

Aplastic Anemia with Epstein-Barr Virus Reactivation after Anti-thymocyte Globulin Therapy
por: Kawarada, Yo, et al.
Publicado: (2023)

Anti-thymocyte globulin (ATG) differentially depletes naïve and memory T cells and permits memory-type regulatory T cells in nonobese diabetic mice
por: Xia, Chang-Qing, et al.
Publicado: (2012)

Transgenic Rabbits That Overexpress the Neonatal Fc Receptor (FcRn) Generate Higher Quantities and Improved Qualities of Anti-Thymocyte Globulin (ATG)
por: Baranyi, Mária, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_r5j4t5497bucs16k4r0k7agar6